Vericel Corp (VCEL) company profile

Vericel Corporation develops and commercializes advanced cell therapies and specialty biologics focused on the sports medicine and severe burn care markets. Its commercial product portfolio features MACI, an autologous cellular scaffold implant and related surgical instruments used by orthopedic surgeons to repair knee cartilage defects in adults. In severe burn care, the company provides Epicel, an autograft skin replacement device for extensive deep-dermal or full-thickness burns, and NexoBrid, an enzymatically active topical biologic for eschar removal in pediatric and adult patients. Vericel markets these therapies across the United States to orthopedic surgeons, hospitals, and specialized burn treatment centers.

The company's commercial operations cover the United States, addressing approximately 140 dedicated burn centers and a nationwide base of orthopedic surgeons. Vericel maintains cell manufacturing and distribution operations at a facility in Cambridge, Massachusetts, alongside a completed 126,000-square-foot manufacturing, laboratory, and office site in Burlington, Massachusetts. NexoBrid manufacturing occurs through a partner primarily in Israel, with raw materials sourced from Taiwan. Corporate and facility operations are based in Massachusetts.

Summary of the business section of Vericel's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“As of December 31, 2025, we employed approximately 398 full-time employees.”